Explore 3 Stock Ideas & Industry Insights Download Free Report

800-234-336
Shopping Cart 0
countryflagNZ
Login

Apyx Medical Inc

Healthcare US APYX

4.26USD
0.18(4.41%)

Last update at 2026-06-24T18:15:00Z

Day Range

4.044.33
LowHigh

52 Week Range

0.834.50
LowHigh

Fundamentals

  • Previous Close 4.08
  • Market Cap163.13M
  • Volume42613
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-5.79100M
  • Revenue TTM52.84M
  • Revenue Per Share TTM1.29
  • Gross Profit TTM 33.04M
  • Diluted EPS TTM-0.27

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -10.83500M -23.30700M -21.28200M -22.91100M -14.82000M
Minority interest -0.10600M 0.10M 0.14M -0.09400M -0.02800M
Net income -11.21100M -23.46300M -18.71300M -23.27800M -15.20000M
Selling general administrative 36.12M 43.12M 48.87M 48.15M 43.73M
Selling and marketing expenses - - 19.64M - -
Gross profit 19.03M 29.36M 33.76M 29.13M 33.60M
Reconciled depreciation 0.66M 0.60M 0.74M 0.89M 0.90M
Ebit -6.44600M -17.40000M -18.80400M -23.56200M -14.44800M
Ebitda -5.79100M -16.80100M -18.11200M -22.89600M -14.81000M
Depreciation and amortization 0.66M 0.60M 0.69M 0.67M -0.36200M
Non operating income net other - - - 0.65M -0.37200M
Operating income -6.44600M -18.84500M -17.25900M -23.56200M -14.44800M
Other operating expenses 59.29M 66.95M 69.61M 68.07M 62.97M
Interest expense 5.59M 5.91M 2.48M 0.01M 0.01000M
Tax provision 0.27M 0.25M -2.36800M 0.37M 0.38M
Interest income 1.11M 1.61M 0.54M 0.16M 0.01M
Net interest income -4.48100M -4.30100M -0.82300M 0.14M 0.00100M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.27M 0.25M -2.43200M 0.37M 0.38M
Total revenue 52.84M 48.10M 52.35M 44.51M 48.52M
Total operating expenses 25.48M 48.20M 51.02M 52.69M 48.05M
Cost of revenue 33.81M 18.74M 18.59M 15.38M 14.92M
Total other income expense net -4.38900M -4.46200M -4.02300M 0.65M -0.37200M
Discontinued operations - - - - -
Net income from continuing ops -11.10500M -23.55900M -15.29100M -23.27800M -15.20000M
Net income applicable to common shares - - - -23.18400M -15.17200M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 66.84M 64.84M 79.24M 51.77M 68.72M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 1.35M 1.66M 2.73M 2.74M 1.93M
Total liab 52.01M 50.51M 52.32M 13.98M 14.71M
Total stockholder equity 14.54M 14.21M 26.70M 37.58M 53.70M
Deferred long term liab - - - - -
Other current liab 8.21M 7.06M 9.17M 8.07M 1.86M
Common stock 0.04M 0.04M 0.04M 0.04M 0.03M
Capital stock 0.04M 0.04M 0.04M 0.04M 0.03M
Retained earnings -89.12200M -77.91100M -54.44800M -35.73500M -12.55100M
Other liab - - - 1.59M 1.49M
Good will - - - - -
Other assets - - - 1.22M 1.11M
Cash 31.74M 31.74M 43.65M 10.19M 30.87M
Cash and equivalents - - - - -
Total current liabilities 11.70M 10.72M 12.74M 11.85M 13.21M
Current deferred revenue - 0.69M 0.49M 0.85M 8.42M
Net debt 7.60M 7.02M -5.15100M -9.39600M -30.56500M
Short term debt 0.43M 0.35M 0.37M 0.25M 0.29M
Short long term debt - - - - -
Short long term debt total 39.34M 38.76M 38.50M 0.80M 0.30M
Other stockholder equity 103.62M 92.08M 81.11M 73.28M 66.22M
Property plant equipment - - - 6.76M 6.58M
Total current assets 58.47M 56.44M 70.36M 42.97M 60.74M
Long term investments - - - - -
Net tangible assets - - - 37.58M 53.70M
Short term investments - - - - -
Net receivables 16.78M 15.48M 14.05M 18.25M 21.16M
Long term debt 34.85M 33.89M 33.19M - -
Inventory 8.60M 7.56M 9.92M 11.80M 6.78M
Accounts payable 3.06M 2.62M 2.71M 2.67M 2.63M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - 0.21M 0.30M
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - 0.00000M - -
Additional paid in capital - - - - -
Common stock total equity - - - 0.04M 0.03M
Preferred stock total equity - - - - -
Retained earnings total equity - - - -35.73500M -12.55100M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 1.75M 1.66M 1.73M 1.22M 1.11M
Deferred long term asset charges - - - - -
Non current assets total 8.37M 8.40M 8.88M 8.80M 7.98M
Capital lease obligations 4.49M 4.87M 5.32M 0.80M 0.30M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.72200M 6.68M -1.01000M -0.72300M
Change to liabilities - - - -1.14100M 4.55M
Total cashflows from investing activities -1.11400M -0.72200M 6.73M -1.01000M -0.72300M
Net borrowings -0.02000M -0.02000M 35.04M -0.14800M -0.23800M
Total cash from financing activities 9.58M 6.75M 32.17M 0.22M 0.02M
Change to operating activities - - - -1.73100M 4.75M
Net income -11.10500M -23.55900M -18.85000M -23.27800M -15.20000M
Change in cash -0.00100M -11.91100M 33.46M -20.67800M -11.04500M
Begin period cash flow 31.74M 43.65M 10.19M 30.87M 41.91M
End period cash flow 31.74M 31.74M 43.65M 10.19M 30.87M
Total cash from operating activities -8.00100M -18.04700M -5.24900M -20.28000M -10.44900M
Issuance of capital stock 9.30M 7.00M 0.00000M - -
Depreciation 0.66M 0.60M 0.69M 0.89M 0.90M
Other cashflows from investing activities - - -0.14700M - -
Dividends paid - - - - -
Change to inventory -1.07400M 2.26M 1.46M -5.56800M -2.85900M
Change to account receivables -1.31800M -2.03500M 3.97M 1.92M -4.90100M
Sale purchase of stock - - - - 0.20M
Other cashflows from financing activities 0.06M -0.23500M -5.59100M 0.36M 0.26M
Change to netincome - - - 7.09M 5.58M
Capital expenditures 1.11M 0.72M 0.53M 1.01M 0.72M
Change receivables - - - 1.92M -4.90100M
Cash flows other operating - - - -0.18800M 1.48M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - -21.07300M -11.14800M
Change in working capital -1.59100M -1.24500M 5.54M -5.21700M -1.84300M
Stock based compensation 2.00M 4.01M 5.11M 6.70M 5.09M
Other non cash items 2.04M 2.15M 2.25M 0.63M 0.60M
Free cash flow -9.11500M -18.76900M -5.78200M -21.29000M -11.17200M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
APYX
Apyx Medical Inc		 0.18 4.41% 4.26 - 72.46 3.09 11.22 3.23 -5.3311
ABT
Abbott Laboratories		 0.53 0.59% 91.06 25.97 17.24 3.57 3.20 3.81 16.75
SYK
Stryker Corporation		 4.65 1.50% 314.65 44.07 24.94 5.51 6.12 6.05 25.73
MDT
Medtronic PLC		 -0.31 0.38% 80.32 26.60 15.87 3.35 2.08 3.90 14.12
BSX
Boston Scientific Corp		 -0.845 1.85% 44.76 31.49 17.24 4.41 3.65 4.88 19.19

Reports Covered

Stock Research & News

View All

Profile

Apyx Medical Corporation, an energy technology company, designs, develops, manufactures, and sells electrosurgical equipment and medical devices in the United States and internationally. The company operates through two segments: Surgical Aesthetics and Original Equipment Manufacturing (OEM). It offers helium plasma generator for the delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures; and a portfolio of single-use handpieces and accessories for open and laparoscopic procedures. The company's helium plasma technology products are marketed and sold under the Renuvion name in the cosmetic surgery market and under the J-Plasma name in the hospital surgical market. It also develops and manufactures OEM generators and related accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.

Apyx Medical Inc

5115 Ulmerton Road, Clearwater, FL, United States, 33760-4004

Key Executives

Name Title Year Born
Mr. Charles D. Goodwin II Pres, CEO & Director 1966
Ms. Tara H. Semb CFO, Treasurer & Sec. 1970
Mr. Moshe Citronowicz Sr. VP 1953
Mr. Todd Hornsby Exec. VP 1976
Mr. Charles D. Goodwin II President, CEO & Director 1967
Mr. Matthew C. Hill CPA CFO, Treasurer & Secretary 1969
Mr. Moshe Citronowicz Senior Vice President 1953
Mr. Todd Hornsby Executive Vice President 1977
Mr. Shawn D. Roman Chief Operating Officer 1972
Ms. Dolores Catania Chief of Confidence NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.